Since the first cloning of a human tumour antigen, melanoma antigen-1 (MAGE-1), the identification of tumour antigens capable of inducing an immune response in cancer patients, and the development of vaccines targeting these antigens, have been formidable tasks confronting tumour immunologists [5,6,9-13]. This evidence concerns the gene SLC45A2 and neoplasm.